Systematic Review or Meta Analysis

The review lays out a multidimensional precision-care model that could help make IBD treatment more personalized, reduce unnecessary continuous medication, and use biomarker and technology-driven adjustments to manage...

Arthritis is a common and meaningful extraintestinal problem for people with IBD; understanding diagnosis and treatment options can help patients and clinicians seek appropriate multidisciplinary care.

A systematic review finds risankizumab (an IL-23 inhibitor) effective and generally well tolerated for moderate-to-severe Crohn's disease and ulcerative colitis, including in patients who failed prior biologics. This...

People with IBD have higher risk of several GI and hepatobiliary cancers; imaging is an important complement to endoscopic surveillance for detecting cancers that may be transmural or outside endoscopic reach.

The review aggregates published instances where combining two advanced immunomodulators was followed by improvement in pyoderma gangrenosum, a serious skin complication often seen in people with IBD. However, the...

PG is often linked with IBD and other systemic conditions, so approaches that treat the underlying comorbidity can improve ulcer healing and lower relapse risk. Patients with IBD who develop PG may benefit from therapies...

The review connects UC pathological features to specific drug-delivery design needs, which could guide development of therapies that reach and act effectively in inflamed colon tissue. For people with UC, better-targeted...

Researchers and clinicians are exploring fungi’s role in IBD beyond bacteria. For patients, seeing Candida in stool tests is usually a signal of microbiome disruption rather than proof of fungal infection that requires...

Achieving histologic or biochemical remission in addition to clinical and endoscopic remission was associated with substantially lower relapse risk in ulcerative colitis across multiple follow-up intervals, suggesting...

Researchers are exploring ferroptosis as a double-edged mechanism: preventing it may protect healthy gut lining in IBD, while inducing it might help treat colorectal cancer. Advances could lead to new biomarkers or...

Research linking ETBF to intestinal inflammation and colorectal cancer suggests better detection and targeted therapies for this microbe could eventually affect IBD management and cancer risk assessment.

The review helps patients, caregivers, clinicians, and researchers know which caregiver-impact PROMs have some validity evidence in pediatric chronic GI disorders and which tools still need more testing before widespread...

Non-invasive biomarkers can help detect and monitor IBD activity, distinguish IBD from other GI conditions, and potentially predict relapse—tools that may reduce need for invasive tests.

Distinguishing Crohn’s disease from intestinal tuberculosis can change treatment (immune suppression versus anti‑tubercular therapy) and outcomes. This review summarizes which findings have tended to favor one diagnosis...

People with IBD may be interested because the review summarizes biological pathways that could link gut inflammation to brain changes seen in Alzheimer’s disease, suggesting possible shared mechanisms and future research...

IBD-U means no clear Crohn’s or ulcerative colitis diagnosis yet — that uncertainty can affect treatment decisions and follow-up. The review highlights tests that may help clarify diagnosis and stresses that many...

People with UC often look for dietary supplements or ‘‘natural’’ add-ons. This review explains which nutraceutical approaches have the most and least clinical support, helping patients and clinicians weigh potential...

Pharmacokinetics affect how well biologic drugs work for IBD. Better PK data could help explain why many patients have inadequate responses and could inform personalized dosing for IL-23p19 inhibitors used in Crohn’s...

Understanding how different forms of programmed cell death in the gut lining contribute to barrier loss and inflammation could point to new therapeutic targets for IBD. The review also flags natural products and...

People with IBD and coexisting primary sclerosing cholangitis (PSC) may get faecal calprotectin tests to monitor colon inflammation. If PSC raises FC independently of colitis, FC could mislead decisions about IBD...

Improving nursing support during IBD trial pathways could help people stay engaged, understand what participation involves, and report problems earlier—potentially making trials safer and more equitable.

The article reviews current and emerging IBD treatments and the biological reasons they may work — useful for patients wanting to understand treatment options and future directions. It highlights therapies beyond...

People with IBD or Crohn's disease considering or taking upadacitinib may worry about rare but serious risks such as heart attacks, strokes, or blood clots. This meta-analysis found no clear increase in those events...

Microbiota-targeting treatments are an active area of IBD research, and biomaterials may help overcome delivery challenges that limit current microbiome therapies. Advances here could improve how well these approaches...

The review shows psychotherapies can improve quality of life and reduce anxiety and depression in people with IBD, outcomes that matter for daily functioning even when intestinal symptoms may not change.

Dietary patterns like the Mediterranean diet may reduce inflammation and improve quality of life for people with Crohn’s disease by beneficially altering the gut microbiome and inflammatory markers. That could offer a...

The review explains why many patients still fail current therapies and summarizes promising new research directions (microRNA, microbiome therapies, stromal cell approaches) that could change treatment strategies.

People with ulcerative colitis face a higher colorectal cancer risk driven in part by chronic inflammation; this review explains the molecular and immune mechanisms behind that risk and highlights biomarkers and...

The review connects animal-model discoveries (IL-23/IL-17 and TNF pathways, gut–joint interactions) to therapies and research priorities relevant to people with SpA and IBD-associated arthritis.

People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.

People with IBD may be interested because probiotics are being explored as a safer, non-immunosuppressive approach to help modulate gut microbiota and reduce inflammation, but effective oral delivery remains a key...

Extraintestinal symptoms such as fatigue and joint pain significantly affect quality of life in Crohn's disease. This review suggests ustekinumab may help reduce fatigue and arthritis/arthralgia more than TNF antagonists...

Many people with IBD try dietary changes to manage symptoms. This review summarizes what published adult studies report and points toward whole-food and Mediterranean-style patterns as commonly supported approaches.

For people hospitalized with acute severe ulcerative colitis, starting a JAK inhibitor together with IV steroids right away (rather than waiting for steroids to fail) could potentially control inflammation sooner and...

This review may help patients and clinicians understand how long-lasting changes in bacterial metabolism could contribute to IBD relapse and point toward future microbiome-targeted therapies aimed at restoring resilient...

Vitamin D appears linked to immune regulation, gut barrier health, and the microbiome—processes relevant to IBD and other intestinal disorders. Understanding this could affect how clinicians monitor and study vitamin D...

This review highlights a potential new class of IBD drugs (RIPK1 inhibitors) that target inflammatory and cell-death pathways implicated in epithelial injury. For people with IBD, it signals an area of active research...

People labelled with IBS-D may actually have treatable organic conditions that require different tests and treatments; avoiding diagnostic mistakes can speed appropriate care and reduce unnecessary symptom-focused...

Understanding how the gut virome shapes regulatory T cells could reveal new biomarkers or therapeutic targets for IBD and related systemic immune diseases. This may help explain unexplained flares or individual...

Biologics and newer small molecules have markedly changed IBD care and outcomes for many patients, but their population-level impact depends on access, cost, and how they are used. Understanding this helps patients and...

This study addresses whether being on biologic or small‑molecule IBD drugs before colorectal surgery affects short‑term postoperative complications — a practical concern for patients and clinicians planning surgery.

Rising incidence in east and southeast Asia means more people will live with IBD over coming decades, which affects healthcare planning, access to specialists, and resource needs. Understanding regional trajectories can...

Depressive disorders—diagnosed using structured clinical interviews—appear to be relatively common in people with IBD, which has implications for screening and referral to mental health care within IBD clinics.

Bile acids shaped by gut microbes can influence inflammation and metabolism, so understanding these pathways could lead to new biomarkers or treatments relevant to people with IBD.

If you have IBD, the mouth and gums may be part of shared inflammatory pathways with your gut. Periodontitis is associated with higher odds of having IBD in cross-sectional studies and has a modest link to later...

Identifies factors that may raise the chance of developing pouchitis after IPAA — useful for patients considering or recovering from proctocolectomy and for clinicians planning perioperative care or monitoring.

Smart, stimuli-responsive nanocarriers could one day allow IBD treatments to act more precisely in the gut and limit side effects; that may matter to people hoping for better-targeted therapies or fewer systemic...

This review suggests Aloe vera polysaccharides could support gut barrier repair, microbiome balance, and immune regulation—mechanisms relevant to IBD inflammation and healing. However, evidence is mainly preclinical and...